V
Voyager Therapeutics
Gene therapies for neurological diseases crossing blood-brain barrier.
At a glance
- Founded
- 2014
- Headquarters
- Cambridge, United States
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later10 investors entered at this stage
Wellington Management
Casdin Capital- BCBrookside Capital
- PSPFM Health Sciences
- USUniversity of Massachusetts Medical School
Fidelity Investments- UCUniversity of California
- SFSan Francisco
Foresite Capital- SUStanford University
Source: Dealroom Talent Intelligence.
Alumni founders
Former Voyager Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
STSeaport TherapeuticsEst. 2024
Steven PaulUnited States
VTVima TherapeuticsEst. 2023
Bernard RavinaUnited States
LTLogicBio TherapeuticsEst. 2015
Mark MdUnited States
GBGeneration BioEst. 2016
Robert KotinUnited StatesGlobal footprint
team presence
across markets
Patents
80 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Voyager Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Voyager Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
